FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:928-930 February 26, 2009 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Acute myeloid leukemia (AML) involves the immortalization of immature myeloid progenitors and is a heterogeneous disease. Current clinical practice separates AML into low-, intermediate-, and high-risk categories according to cytogenetic anomalies. Among the low-risk subtypes of AML is acute promyelocytic leukemia (APL). Approximately 98% of persons with APL carry a translocation of chromosomes 15 and 17, typically resulting in the fusion between RAR (retinoic acid receptor ), which encodes a retinoic acid receptor, and the promyelocytic leukemia (PML) protein. These persons are treated with all-trans retinoic acid in combination with chemotherapy; this treatment results in prolonged remission in more . . . [Full Text of this Article]

Source Information

From the Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago.

This article has been cited by other articles:

• Nasr, R., Lallemand-Breitenbach, V., Zhu, J., Guillemin, M.-C., de The, H. (2009). Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure. Clin. Cancer Res. 15: 6321-6326 [Abstract] [Full Text]